SCHEMBL4349747

SCHEMBL4349747

CNc1ccc2cccnc2c1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 6/20 0.56
TSHR P16473 2/20 0.52
TDP1 Q9NUW8 2/20 0.52
LMNA P02545 2/20 0.52
KDM4E B2RXH2 1/20 0.52
GMNN O75496 1/20 0.52
TP53 P04637 1/20 0.52
HSP90AA1 P07900 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
MAPT P10636 1/20 0.52
MMP9 P14780 1/20 0.52
ALOX15 P16050 1/20 0.52
NFKB1 P19838 1/20 0.52
MMP8 P22894 1/20 0.52
CCR1 P32246 1/20 0.52
THPO P40225 1/20 0.52
MTOR P42345 1/20 0.52
HTT P42858 1/20 0.52
MMP13 P45452 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8342736 0.80 MMP2 (0.55) MMP2TDP1LMNAKDM4ETP53
SCHEMBL10309544 0.80 LMNA (0.59) MMP2TSHRTDP1LMNAKDM4E
SCHEMBL19669699 0.80 LMNA (0.54) MMP2TSHRTDP1LMNAKDM4E
SCHEMBL15961561 0.78 MMP2 (0.56) MMP2TSHRTDP1LMNAKDM4E
SCHEMBL4546341 0.77 TDP1 (0.62) MMP2TSHRTDP1LMNAKDM4E
SCHEMBL10309555 0.76 TDP1 (0.48) MMP2TSHRTDP1LMNAKDM4E
SCHEMBL623096 0.76 LMNA (0.63) MMP2TSHRTDP1LMNAKDM4E
Hydrochloric Acid SCHEMBL28172351 0.76 TDP1 (0.60) MMP2TSHRTDP1LMNAKDM4E
SCHEMBL16029958 0.75 TDP1 (0.52) MMP2TSHRTDP1LMNAKDM4E
SCHEMBL4063648 0.75 MMP2 (0.63) MMP2TSHRTDP1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2136806-A1 METHOD AND MEANS FOR PREVENTING AND INHIBITING TYPE III SECRETION IN INFECTIONS CAUSED BY GRAM-NEGATIVE BACTERIA Creative Antibiotics Sweden AB (SE) 2009-12-30 EP claimed
WO-2008115118-A1 METHOD AND MEANS FOR PREVENTING AND INHIBITING TYPE III SECRETION IN INFECTIONS CAUSED BY GRAM-NEGATIVE BACTERIA INNATE PHARMACEUTICALS AB (SE) 2008-09-25 WO claimed
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression SIERRA SCIENCES, INC. (US) 2023-07-18 US disclosed
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression SIERRA SCIENCES, INC. (US) 2023-07-18 US disclosed
EP-2136806-A1 METHOD AND MEANS FOR PREVENTING AND INHIBITING TYPE III SECRETION IN INFECTIONS CAUSED BY GRAM-NEGATIVE BACTERIA Creative Antibiotics Sweden AB (SE) 2009-12-30 EP disclosed
WO-2008115118-A1 METHOD AND MEANS FOR PREVENTING AND INHIBITING TYPE III SECRETION IN INFECTIONS CAUSED BY GRAM-NEGATIVE BACTERIA INNATE PHARMACEUTICALS AB (SE) 2008-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression TERT, TERF2, RNGTT MMP2 761/4885TSHR 2636/4885TDP1 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.